DURHAM, N.C., October 30, 2026 – OraLiva, Inc., an early cancer detection company developing AI-enabled cytology diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to ORAL ONC-InCYT, an investigational test designed to help clinicians assess suspicious white or red oral lesions. ORAL ONC-InCYT analyzes cells collected from […] The post FDA Grants Breakthrough Device Designation to OraLiva’s Cytology Test for Suspicious Oral Lesions appeared first on OraLiva .